Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 14, 2019

SELL
$3.98 - $6.2 $49,367 - $76,904
-12,404 Closed
0 $0
Q1 2019

Apr 12, 2019

BUY
$2.0 - $4.4 $24,808 - $54,577
12,404 New
12,404 $23,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $493M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.